Table 1.
Demographic and clinical data characteristics of the enrolled subjects
| Demographic characters | Control n=10 |
HIV n=10 |
HCV n=10 |
HIV/HCV n=10 |
|---|---|---|---|---|
| Sex | ||||
| Male | 4 | 10 | 6 | 7 |
| Age | ||||
| Range | 42–64 | 24–54* | 47–67 | 46–54 |
| (Average±SD) | (56±6.8) | (43±10.7) | (56.8±6.6) | (49.1±6.3) |
| Race | ||||
| White | 7 | 7 | 4 | 5 |
| A–A | 3 | 2 | 6 | 5 |
| Others | 0 | 1 | 0 | 0 |
| Antiretroviral treatment | NA | 10 | NA | 10 |
| HCV treatment | NA | NA | 3 | 7 |
| CD4 counts (cells/μL) | ||||
| Range | 420–890 | 310–550† | 520–1060 | 320–960 |
| (Average±SD) | (699±138) | (472±183) | (773±180) | (603±233) |
| HCV viral load (106 IU/mL) | ||||
| Range | NA | NA | 0.09–6.3 | 0–7.5 |
| (Average±SD) | (2.9±2.3) | (2.5±4.3) | ||
| HIV viral load (copies/mL) | ||||
| Range | NA | 0–6670 | NA | 0–110 |
| (Average±SD) | (805±2087) | (43±34) | ||
| Alanine Aminotransferase (ALT) (U/L) | ||||
| Range | 12–35 | 12–46 | 20–97 | 17–82 |
| (Average±SD) | 22.5±7.6 | 23.3±10.1 | 44.8±27.2 | 37.8±18.8 |
| Aspartate Aminotransferase (AST) (U/L) | ||||
| Range | 14–47 | 16–52 | 22–124 | 18–78 |
| (Average±SD) | 24.3±9.7 | 23.5±10.8 | 57.4±33.7 | 40.2±18 |
Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) are significantly different among the groups (p<0.001), and significantly higher (p<0.05) in HCV mono-infected and HCV/HIV coinfected patients compared with controls.
*
Age: There is a significant difference (p<0.01) between HIV and other groups.
†
CD4 counts: There are significant differences between CD4 counts in HIV and control or HCV (p<0.05 and p<0.01, respectively).